InsidersTradesSigma
Total declarations
Companies
▲ Purchases (9 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
9
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-13.3%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by LoConti Joseph E., Executive. Officer active across 3 companies, notably Vitality Biopharma, Inc.. In total, 9 disclosures have been logged. Breakdown: 9 buys · 0 sell. Total volume traded: €1.4m. History available since 29 May 2019. The latest transaction was filed on 7 April 2025 (Acquisition). Regulator: SEC (Form 4). All data is free.
Declarations9 total
3,000 shares@ US$0.1290.1% of flowCommon Stock, par value $0.001 per shareSEC:0001641172-25-008777:0
Ideal exit: 2 Jan 2026 (T+270)
5,000 shares@ US$0.200.2% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-25-008029:0
Ideal exit: 25 Oct 2025 (T+270)
49,579 shares@ US$0.151.4% of flowCommon Stock, par value $0.001 per shareSEC:0001025708-25-000002:0
Ideal exit: 7 Sept 2024 (T+270)
3,333,333 shares@ US$0.1597.3% of flowCommon Stock, par value $0.001 per shareSEC:0001025708-25-000001:0
Ideal exit: 18 Oct 2025 (T+270)
35,812 shares@ US$0.151.0% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-23-044935:0
Ideal exit: 7 Sept 2024 (T+270)
666,667 shares0Common Stock, par value $0.001 per shareSEC:0001025708-23-000001:0
Ideal exit: 26 Jul 2024 (T+270)
6,666,667 shares@ US$0.150.0001% mcap100.0% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-22-013078:0
Ideal exit: 4 Feb 2023 (T+270)
10,000 shares@ US$0.240.059% mcap50.0% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-21-021306:0
Ideal exit: 23 Feb 2020 (T+270)
10,000 shares@ US$0.2450.0% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-21-021306
Ideal exit: 23 Feb 2020 (T+270)
9 of 9 declarations
About LoConti Joseph E.
Joseph E. LoConti is an executive at Vitality Biopharma, Inc. and Malachite Innovations, Inc., two companies focused on developing biopharmaceutical solutions. His role allows him to contribute to strategic direction and operational optimization. Joseph E. LoConti is committed to promoting innovation and efficiency within these companies.
